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A bs tr ac t
Background
Adrenocortical carcinoma is a rare cancer that has a poor response to cytotoxic 
treatment.
Methods
We randomly assigned 304 patients with advanced adrenocortical carcinoma to re-
ceive mitotane plus either a combination of etoposide (100 mg per square meter of 
body-surface area on days 2 to 4), doxorubicin (40 mg per square meter on day 1), and 
cisplatin (40 mg per square meter on days 3 and 4) (EDP) every 4 weeks or streptozocin 
(streptozotocin) (1 g on days 1 to 5 in cycle 1; 2 g on day 1 in subsequent cycles) 
every 3 weeks. Patients with disease progression received the alternative regimen as 
second-line therapy. The primary end point was overall survival.
Results
For first-line therapy, patients in the EDP–mitotane group had a significantly higher 
response rate than those in the streptozocin–mitotane group (23.2% vs. 9.2%, 
P<0.001) and longer median progression-free survival (5.0 months vs. 2.1 months; 
hazard ratio, 0.55; 95% confidence interval [CI], 0.43 to 0.69; P<0.001); there was no 
significant between-group difference in overall survival (14.8 months and 12.0 months, 
respectively; hazard ratio, 0.79; 95% CI, 0.61 to 1.02; P = 0.07). Among the 185 patients 
who received the alternative regimen as second-line therapy, the median duration of 
progression-free survival was 5.6 months in the EDP–mitotane group and 2.2 months 
in the streptozocin–mitotane group. Patients who did not receive the alternative 
second-line therapy had better overall survival with first-line EDP plus mitotane 
(17.1 month) than with streptozocin plus mitotane (4.7 months). Rates of serious 
adverse events did not differ significantly between treatments.
Conclusions
Rates of response and progression-free survival were significantly better with EDP plus 
mitotane than with streptozocin plus mitotane as first-line therapy, with similar rates 
of toxic events, although there was no significant difference in overall survival. 
(Funded by the Swedish Research Council and others; FIRM-ACT ClinicalTrials.gov 
number, NCT00094497.)
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A drenocortical carcinoma is a rare cancer (estimated incidence, 0.7 to 2.0 cases per 1 million population per year)1,2 with 
a poor prognosis; the 5-year survival rate is less 
than 15% among patients with metastatic dis-
ease.3-7 Mitotane is the only drug approved for 
the treatment of adrenocortical carcinoma and is 
used both as adjuvant therapy and for advanced 
disease,8-14 although its efficacy has never been 
shown in a randomized trial. The experience with 
other antineoplastic drugs for the treatment of 
this disease is even more limited. Current treat-
ment strategies for advanced disease are based ex-
clusively on retrospective series and small phase 
2 trials.
During the International Consensus Confer-
ence on adrenocortical carcinoma in 2003,15 the 
first randomized phase 3 trial of treatment for 
this rare tumor was planned. In this trial, called 
the First International Randomized Trial in Lo-
cally Advanced and Metastatic Adrenocortical 
Carcinoma Treatment (FIRM-ACT), we compared 
the two most successful regimens in patients with 
advanced disease. One regimen, which combined 
etoposide, doxorubicin, and cisplatin (EDP) with 
mitotane, had resulted in an objective response 
rate of 53% in a study involving 28 patients with 
advanced adrenocortical carcinoma.16 The second 
regimen, which combined streptozocin with 
mitotane, had resulted in an objective response 
rate of 36% in a study involving 22 patients with 
advanced adrenocortical carcinoma.17 The goal of 
the trial was to establish a treatment standard for 
advanced disease.
Me thods
Patients
Eligibility criteria were an age of 18 years or older; 
histologically confirmed and radiologically mea-
surable adrenocortical carcinoma that was not 
amenable to radical surgical resection; no previous 
treatment with cytotoxic drugs, except mitotane; 
an Eastern Cooperative Oncology Group (ECOG) 
performance status of 0, 1, or 2 (0, asymptomatic; 
1, symptomatic but ambulatory; and 2, symptom-
atic and in bed <50% of the day); adequate hema-
tologic and biochemical function; and no history 
of another cancer. (Detailed inclusion and exclu-
sion criteria are provided in Table S1 in the Sup-
plementary Appendix, available with the full text 
of this article at NEJM.org.)
Study Design
This study was an investigator-initiated, random-
ized, controlled, open-label, parallel-group trial 
that was conducted in 12 countries at 40 special-
ized centers for the treatment of adrenocortical 
carcinoma. After registration, patients were ran-
domly assigned to receive either EDP plus mitotane 
or streptozocin (streptozotocin) plus mitotane 
with the use of concealed 1:1 randomization by 
the data center in Uppsala, Sweden. The technique 
of randomly permuted balanced blocks and ran-
dom block size was used.
The trial conformed to the principles of the 
Declaration of Helsinki and the Good Clinical 
Practice Guidelines and was approved by the ethics 
committee at each study center. All patients pro-
vided written informed consent. An independent 
data and safety monitoring board supervised the 
collection of efficacy and safety data (board mem-
bers are listed in the Supplementary Appendix).
The protocol committee and the study statisti-
cian designed the study and wrote the first draft 
of the manuscript; the final draft was approved by 
all the authors. (The protocol, with the statistical 
analysis plan, is available at NEJM.org.) In accor-
dance with the regulations of European Medi-
cines Agency, one institution was selected to be 
legally responsible for conducting the study, and 
Uppsala University Hospital accepted this role. 
The drugs were purchased through the regular 
health care plans of the patients. No commer-
cial entity was involved in this trial. Data were 
collected at Uppsala University and statistically 
analyzed at the Universities of Marburg and 
Munich, Germany. All authors vouch for the 
accuracy of the data and the fidelity of the 
study to the protocol. Only investigators par-
ticipating in the trial were involved in the de-
sign of the trial, the analysis of the data, and 
the writing of the manuscript. No one who is not 
an author contributed to the preparation of the 
manuscript.
On the basis of the results of the phase 2 tri-
als,16,17 we anticipated a high percentage of treat-
ment failures during first-line therapy. Therefore, 
the protocol specified provision of second-line 
therapy with the alternative regimen for all pa-
tients who had either disease progression or 
unacceptable toxic events with the assigned regi-
men. Accordingly, two parallel phase 2 trials 
for second-line treatment were embedded in the 
study design.
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Study Treatment
The EDP–mitotane regimen consisted of etoposide 
at a dose of 100 mg per square meter of body-
surface area administered intravenously on days 
2, 3, and 4 of each cycle; doxorubicin at a dose of 
40 mg per square meter given intravenously on 
day 1; cisplatin at a dose of 40 mg per square 
meter given intravenously on days 3 and 4; and 
oral mitotane administered continuously. One cycle 
of the regimen was defined as a 4-week interval. 
The streptozocin–mitotane regimen consisted of 
streptozocin given intravenously at a dose of 1 g 
for 5 days in the first cycle and 2 g on day 1 in 
subsequent cycles, with continuous oral adminis-
tration of mitotane. One cycle of the regimen was 
defined as a 3-week interval.
In both treatment schedules, mitotane was 
started a minimum of 1 week before the initiation 
of the cytotoxic treatment, with the goal of at-
taining a blood level of 14 to 20 mg per liter.8,9 
Since adjuvant mitotane therapy is frequently used 
in patients with adrenocortical carcinoma,10 pre-
vious treatment with mitotane before study entry 
was allowed. Concomitant medications and ther-
apies that were deemed to be necessary for the 
supportive care and safety of the patients were also 
allowed at the discretion of the local investigators. 
Glucocorticoid replacement was recommended in 
all patients except those with persistent Cushing’s 
syndrome.
Study Assessments
Patients were seen at the start of every treatment 
cycle for physical examination, determination of 
ECOG performance status, a complete blood count, 
and serum biochemical measurements. Tumor re-
sponse, measured according to the Response Eval-
uation Criteria in Solid Tumors (RECIST) 1.0,18 
was assessed every 8 weeks by means of thoracic 
and abdominal computed tomography or magnetic 
resonance imaging (Text 1 in the Supplementary 
Appendix). We calculated overall survival and pro-
gression-free survival as the time from the date of 
randomization until the date of death and the date 
of disease progression, respectively. Death was re-
corded as related or not related to progressive ad-
renocortical carcinoma. Data for patients who 
survived and for those surviving without disease 
progression were censored at the date of the last 
follow-up visit and the date of the last tumor-
response assessment, respectively. We assessed 
quality of life every 8 weeks using the European 
Organization for Research and Treatment of 
Cancer (EORTC) quality-of-life core question-
naire (QLQ-C30, version 3.0).19 Safety assess-
ments were performed before each treatment cy-
cle with the use of the National Cancer Institute 
Common Terminology Criteria for Adverse Events, 
version 2.0.19 Expected toxic events were recorded 
only if they met established criteria for a serious 
adverse event.20
End Points
The primary end point was overall survival, and 
secondary end points were progression-free sur-
vival, tumor response, and quality of life. Sec-
ondary objectives were to explore the effect of a 
blood mitotane level of 14 to 20 mg per liter on 
the clinical outcome and to determine the re-
sponse to each of the two regimens as second-
line treatment.
Statistical Analysis
The trial was designed to have a power of 80% to 
detect a risk reduction of 33% in the EDP–mitotane 
group, as compared with the streptozocin–mito-
tane group. We determined that such an analysis 
would require the observation of up to 200 deaths 
on the basis of a two-sided group sequential log-
rank test at a type I error level of 5%. All analy-
ses were performed on an intention-to-treat 
basis. Overall survival and progression-free sur-
vival were analyzed with the use of the Kaplan–
Meier method and compared between groups by 
means of the log-rank test. A Cox proportional-
hazards model was used to estimate the hazard 
ratios. Rates of best overall tumor response to 
treatment were estimated, with 95% confidence 
intervals, by using the method of Clopper and 
Pearson and were compared by using exact meth-
ods for testing and estimating (e.g., Fisher’s ex-
act test and exact confidence intervals for odds 
ratios).
Serious adverse events were described according 
to the treatment period, with the omission of 
deaths from progression of adrenocortical carci-
noma. The numbers of events per patient and per 
month of therapy were compared between treat-
ment groups with the use of the exact Wilcoxon–
Mann–Whitney test and Poisson-regression analy-
sis, respectively. The global health score on the 
QLQ-C30 and the absolute change in the score 
from baseline were used as summary measures of 
the quality of life and were compared between 
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groups with the use of the Wilcoxon–Mann–
Whitney test. (Further details are provided in Text 
2 in the Supplementary Appendix.)
R esult s
Patients
From June 2004 through October 2009, a total of 
304 patients were enrolled in the study. The data-
base was closed for final analysis on December 
10, 2010. Demographic characteristics of the 
patients and baseline clinical characteristics that 
are considered to be clinically relevant21 were 
well balanced between the two study groups 
(Table 1).
Administered Treatments
At least one cycle of chemotherapy was adminis-
tered in 148 patients in the EDP–mitotane group 
and in 149 patients in the streptozocin–mitotane 
group (safety cohort) (Fig. 1). In total, 605 cy-
cles of EDP (scheduled every 28 days) and 631 
cycles of streptozocin (scheduled every 21 days) 
were given as first-line therapy (Table S2 in the 
Supplementary Appendix). The alternative regi-
men was administered as second-line treatment 
in 185 patients (EDP–mitotane in 101 patients 
and streptozocin–mitotane in 84 patients). How-
ever, 119 patients did not receive the second-line 
therapy for a variety of reasons (e.g., rapid tu-
mor progression, toxic events that precluded 
further treatment, and successful first-line 
therapy).
Efficacy
Treatment Response and Progression-free Survival
An objective tumor response occurred in 35 of 
151 patients in the EDP–mitotane group, as com-
pared with 14 of 153 patients in the streptozocin–
mitotane group (23.2% vs. 9.2%, P<0.001). Three 
patients had a complete response, and 6 patients 
were rendered disease-free by surgery after a par-
tial response to the study treatment (Table 2).
Tumor progression occurred in 280 of 304 
patients (92.1%). The median duration of progres-
sion-free survival was 5.0 months (95% confidence 
interval [CI], 3.5 to 6.9) in the EDP–mitotane 
group, as compared with 2.1 months (95% CI, 
2.04 to 2.33) in the streptozocin–mitotane group 
(hazard ratio, 0.55; 95% CI, 0.43 to 0.69; P<0.001) 
(Fig. 2A). At 12 months, 26.1% of patients (95% 
CI, 19.0 to 33.1) who received first-line therapy 
with EDP plus mitotane were alive without dis-
ease progression, as compared with 7.2% (95% 
CI, 3.1 to 11.3) who received first-line therapy 
with streptozocin plus mitotane.
Table 1. Baseline Characteristics in the Intention-to-Treat Population.*
Characteristic
EDP-M
(N = 151)
Sz-M
(N = 153)
Age — yr
Median 51.9 50.0
Range 19.0–76.2 18.8–72.8
Sex — no. (%)
Male 60 (39.7) 61 (39.9)
Female 91 (60.3) 92 (60.1)
Tumor stage — no. (%)
III 0 1 (0.7)
IV 151 (100.0) 152 (99.3)
Endocrine symptoms — no. (%)
Cushing’s syndrome with or without other 
symptoms
60 (39.7) 64 (41.8)
Conn’s syndrome only 2 (1.3) 3 (2.0)
Virilization only 6 (4.0) 7 (4.6)
Feminization only 3 (2.0) 2 (1.3)
No symptoms 70 (46.4) 68 (44.4)
Missing data 10 (6.6) 9 (5.9)
ECOG performance status score — no. (%)
0 73 (48.3) 72 (47.1)
1 64 (42.4) 60 (39.2)
2 13 (8.6) 21 (13.7)
4 1 (0.7)† 0
Time since primary diagnosis — mo‡
Median 7.3 4.5
Range 0–183.7 0–111.6
No. of affected sites§
Median 3 3
Range 1–7 1–8
Blood mitotane level
No. of analyzed samples 130 136
Median — mg/liter 6.3 5.1
Range — mg/liter 0–33.0 0–56.0
* There were no significant differences between groups, except as indicated. 
EDP-M denotes etoposide, doxorubicin, and cisplatin plus mitotane, and 
Sz-M streptozocin plus mitotane.
† In this patient, a score of 4 on the Eastern Cooperative Oncology Group 
(ECOG) scale was related to a preexisting disability from stroke.
‡ P<0.05.
§ The following sites were calculated as separate sites of adrenocortical carcinoma: 
adrenal gland (including local recurrence), liver, lung, bone, peritoneum,  
retroperitoneum, pleura, mediastinum, central nervous system, soft tissue, 
spleen, and ovary.
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Overall Survival
At final analysis, 232 patients (76.3%) had died, 
with 211 deaths caused by progressive disease 
(90.9%); 18 deaths were from causes other than 
cancer (infection in 6 patients, organ failure in 
5, pulmonary embolism in 3, cardiovascular events 
in 3, and hemorrhage in 1), and 3 deaths were from 
unknown causes. Three deaths were classified as 
probably related to the EDP–mitotane regimen 
(infection in 2 patients and a cardiovascular event 
in 1) and 1 as possibly related to this regimen (a 
death of unknown cause 3 weeks after the ad-
ministration of EDP plus mitotane). In addition, 
1 patient died from liver failure 11 days after the 
start of treatment with streptozocin; this death 
was classified as most likely to be related to both 
the study treatment and progressive disease.
Among patients receiving first-line therapy, 
there were 108 deaths in the EDP–mitotane group 
and 124 in the streptozocin–mitotane group; the 
median duration of survival was 14.8 months (95% 
CI, 11.3 to 17.1) and 12.0 months (95% CI, 10.3 to 
13.6), respectively (Fig. 2B). Thus, EDP plus mito-
tane as first-line treatment reduced the risk of 
death by 21%, as compared with streptozocin plus 
mitotane (hazard ratio, 0.79; 95% CI, 0.61 to 1.02; 
P = 0.07) in the intention-to-treat analysis. (The 
results of additional per-protocol analyses are pro-
vided in Text 3 in the Supplementary Appendix.)
Subgroup Analyses
Hazard ratios for disease recurrence and death 
according to prespecified baseline factors are 
provided in Figure S1 in the Supplementary Ap-
pendix. These analyses show that the EDP–mito-
tane regimen had similar efficacy in most sub-
groups. A total of 54 patients had a blood 
mitotane level of 14 mg per liter or higher at 
baseline, and there was a trend toward increased 
overall survival among these patients as com-
pared with the 212 patients who had a blood mi-
totane level of less than 14 mg per liter (hazard 
ratio for death, 0.76; 95% CI, 0.54 to 1.08; 
P = 0.13).
Second-Line Therapy
The efficacy of both regimens as second-line ther-
apy was similar to their efficacy as first-line thera-
py, with a median progression-free survival of 5.6 
months (95% CI, 3.6 to 7.4) among the 101 patients 
receiving second-line EDP plus mitotane and 2.2 
months (95% CI, 2.0 to 2.6) among the 84 patients 
receiving second-line streptozocin plus mitotane. 
The median duration of survival from the start of 
second-line therapy was 10.3 months (95% CI, 
8.8 to 12.6) and 7.4 months (95% CI, 6.3 to 9.2) in 
the two groups, respectively. (Additional subgroup 
analyses are provided in Text 3 in the Supplemen-
tary Appendix.)
Second-Line
Therapy
304 Patients underwent randomization
151 Were assigned to EDP-M group 153 Were assigned to Sz-M group
3 Were not treated 4 Were not treated
84 Underwent 335 cycles of Sz-M
as second-line therapy (range, 1–18)
101 Underwent 416 cycles of EDP-M
as second-line therapy (range, 1–10)
148 Underwent 605 cycles of first-line
therapy (range, 1–10)
149 Underwent 631 cycles of first-line
therapy (range, 1–36)Safety Cohort
Intention-to-
Treat Cohort
Figure 1. Enrollment and Treatment.
EDP-M denotes etoposide, doxorubicin, and cisplatin plus mitotane, and Sz-M streptozocin plus mitotane.
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Quality of Life and Safety
The rate of compliance with the quality-of-life 
questionnaire was 67.1% at baseline (204 of all 
304 patients) and 46.1% at the time of the first 
evaluation (129 of the 280 patients who were still 
alive). The median score was the same in the EDP–
mitotane group and the streptozocin–mitotane 
group, both at baseline (58) and at the first evalu-
ation (50), with no significant difference between 
the two evaluations (Table S3 in the Supplementary 
Appendix).
During the first-line therapy, 47 patients in the 
EDP–mitotane group had 86 serious adverse events, 
as compared with 37 patients with 62 serious ad-
verse events in the streptozocin–mitotane group 
(P = 0.16) (Table 3). The numbers of serious adverse 
events per month were similar in the two study 
groups (0.092 per month in the EDP–mitotane 
group and 0.099 per month in the streptozocin–
mitotane group, P = 0.64). The findings were 
similar for the first 8 weeks of treatment, with 
45 serious adverse events in 25 patients in the 
EDP–mitotane group and 33 such events in 26 
patients in the streptozocin–mitotane group 
(P = 0.96). Similarly, the rate of nonserious adverse 
events did not differ significantly between the 
two study groups (0.54 per month in the EDP–
mitotane group and 0.49 per month in the strep-
tozocin–mitotane group, P = 0.17).
Discussion
In our study, EDP plus mitotane administered as 
first-line therapy in patients with advanced adre-
nocortical carcinoma resulted in a higher rate of 
objective tumor response than did streptozocin 
plus mitotane (23.2% vs. 9.2%), with a significant 
increase in progression-free survival (5.3 months 
vs. 2.0 months) and a significantly higher percent-
age of patients without progression at 12 months 
(26.1% vs. 7.2%). These findings suggest that EDP 
plus mitotane, as compared with streptozocin 
plus mitotane, had superior antitumor efficacy in 
the patients. However, despite these positive re-
sults, the overall survival rates in our study re-
mained dismal. First-line therapy with EDP plus 
mitotane did not translate into a significant im-
provement in overall survival, as compared with 
streptozocin plus mitotane (14.8 months vs. 12.0 
months, P = 0.07).
Several explanations might account for this 
finding, including a poorer prognosis than antici-
pated16,17 and a smaller effect size than initially 
hypothesized. To provide patients with the best 
salvage therapy and to control for second-line 
treatments, the alternative regimen was included 
in the protocol for all patients with disease pro-
gression. Thus, two parallel phase 2 trials for 
second-line treatment were embedded in the study 
design. Although a direct statistical comparison of 
the results of the second-line regimens is poten-
tially biased, the rate of progression-free survival 
with the two second-line regimens (5.6 months 
with EDP plus mitotane vs. 2.0 months with strep-
tozocin plus mitotane) replicated the rates ob-
served with first-line therapy, again pointing to 
a greater efficacy for EDP plus mitotane. Thus, 
the EDP–mitotane regimen was superior as first-
line therapy and was also effective as second-line 
therapy. The efficacy of EDP plus mitotane as 
second-line therapy probably attenuated its ad-
vantage as first-line therapy and affected the 
overall survival analysis. Furthermore, it has re-
cently been reported that mitotane is a potent 
inducer of CYP3A4 activity,22,23 which may have 
reduced the blood levels of doxorubicin and eto-
Table 2. Best Overall Response in the Intention-to-Treat Population.*
Variable
EDP-M
(N = 151)
Sz-M
(N = 153) P Value
Type of response — no. (%)
Complete response 2 (1.3) 1 (0.7)
Disease-free by time  
of surgery†
4 (2.6) 2 (1.3)
Partial response 29 (19.2) 11 (7.2)
Stable disease‡ 53 (35.1) 34 (22.2)
Progressive disease 43 (28.5) 88 (57.5)
Did not receive treatment 3 (2.0) 4 (2.6)
Could not be evaluated  
for response
17 (11.3) 13 (8.5)
Objective response§
No. of patients 35 14
% (95% CI) 23.2 (16.7–30.7) 9.2 (5.1–14.9) <0.001
Disease control¶
No. of patients 88 48
% (95% CI) 58.3 (50.0–66.2) 31.4 (24.1–39.4) <0.001
* Responses were rated according to the Response Evaluation Criteria in Solid 
Tumors (RECIST).
† Surgery was performed after a partial response to study treatment. These pa-
tients were not included in the “partial response” category.
‡ Stable disease was defined as no disease progression for at least 8 weeks and 
no objective response to treatment. Confirmatory scans were not required for 
this determination, according to the study protocol.
§ Objective response was defined as a complete or partial response.
¶ Disease control was defined as a complete response, a partial response, or 
stable disease.
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poside, both of which are metabolized by CY-
P3A4. In theory, this could have attenuated the 
efficacy of the EDP–mitotane regimen. However, 
since no monitoring of the blood levels of these 
drugs was performed, we cannot evaluate these 
hypotheses.
The quality-of-life scores were the same in the 
two study groups. However, compliance in answer-
ing the questionnaires was only about 50%, thus 
limiting the interpretation of the data. As expect-
ed, the profile of serious adverse events differed 
between the two groups, but there was no sig-
nificant between-group difference in the rate of 
such events.
Both treatment regimens contained the adreno-
lytic compound mitotane, which is still the only 
drug licensed for the treatment of adrenocortical 
carcinoma. Several small studies have suggested 
that the antineoplastic activity of mitotane mono-
therapy is increased at blood drug levels of 14 mg 
per liter or higher.8,9,24 In our study, only 54 pa-
tients had such blood mitotane levels at the time 
of enrollment, with a similar distribution in the 
two study groups. Thus, any antitumor activity of 
mitotane is unlikely to have been a major con-
founder of the observed first-line efficacy of the 
EDP–mitotane regimen. There was a trend toward 
increased overall survival among these 54 patients 
as compared with the 212 patients with a mitotane 
level of less than 14 mg per liter (hazard ratio for 
death, 0.76), although the small numbers require 
caution in the interpretation of this observation.
One of the strengths of our trial was the size of 
the study cohort, which was larger than the com-
bined number of participants enrolled in all pub-
lished phase 2 trials of treatment for adrenocorti-
cal carcinoma. An international network of closely 
collaborating investigators was the key to achiev-
ing this enrollment of patients within only 5.4 
years, which is equivalent to a recruitment rate of 
56 patients per year, as compared with a maximum 
of 7 patients per year in previous studies.17,25-28 
This successful enrollment shows that an inves-
tigator-initiated, randomized phase 3 trial of treat-
ment in patients with a rare tumor is feasible, despite 
the lack of pharmaceutical interest in sponsoring 
such a trial. Further strengths of the trial include 
its prospective, randomized design; the intention-
to-treat analysis; the high percentage of patients 
who were evaluated for the predefined end points; 
and the small number of censored observations. 
In addition, the trial was conducted in 12 countries 
on three continents, and the inclusion criteria were 
broad, with few exclusion criteria. Thus, the study 
population can be considered to be representative 
of the overall population of patients with advanced 
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Figure 2. Progression-free and Overall Survival during First-Line Therapy.
Panel A shows Kaplan–Meier estimates for progression-free survival dur-
ing first-line therapy. The median duration of progression-free survival 
was 5.0 months in the EDP-M group and 2.1 month in the Sz-M group. 
Panel B shows Kaplan–Meier estimates for overall survival, with a median 
of 14.8 months in the EDP-M group and 12.0 months in the Sz-M group.
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adrenocortical carcinoma, and the findings should 
be generalizable to this larger population.
Although new targeted therapies have been 
successfully introduced for various cancers, the 
initial results of small studies evaluating such 
therapies in patients with adrenocortical carci-
noma have been disappointing.29-34 The tumor 
response in our study compares favorably with 
the results obtained with these novel therapies. 
Nonetheless, the poor overall survival rates in our 
study confirm the poor prognosis for patients with 
advanced adrenocortical carcinoma and the need 
for improved treatment options.
In summary, although a significant improve-
ment in overall survival was not achieved with EDP 
plus mitotane as first-line therapy, this regimen 
had higher antitumor efficacy as both first- and 
second-line therapy than did streptozocin plus 
mitotane, with a similar rate of serious adverse 
events.
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Table 3. Serious Adverse Events during First-Line Therapy.
Event
EDP-M
(N = 148)
Sz-M
(N = 149)
no. of patients (%)
Any serious adverse event 86 (58.1) 62 (41.6)
Adrenal insufficiency 5 (3.4) 1 (0.7)
Bone marrow toxicity 17 (11.5) 3 (2.0)
Cardiovascular or thromboembolic event 10 (6.8) 0
Fatigue or general health deterioration 8 (5.4) 7 (4.7)
Gastrointestinal disorder 6 (4.1) 12 (8.1)
Impaired liver function 0 7 (4.7)
Impaired renal function 1 (0.7) 6 (4.0)
Infection 10 (6.8) 4 (2.7)
Neurologic toxicity 5 (3.4) 4 (2.7)
Respiratory disorder 9 (6.1) 5 (3.4)
Other 15 (10.1) 13 (8.7)
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